Recent Analysts’ Ratings Updates for Syndax Pharmaceuticals (SNDX)

Several analysts have recently updated their ratings and price targets for Syndax Pharmaceuticals (NASDAQ: SNDX):

• 10/1/2026 – Syndax Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
• 10/1/2026 – Syndax Pharmaceuticals had its “buy” rating reaffirmed by UBS Group AG.
• 9/29/2026 – Syndax Pharmaceuticals had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $35.00 price target on the stock.
• 9/16/2026 – Syndax Pharmaceuticals was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/21/2026 – Syndax Pharmaceuticals was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/21/2026 – Syndax Pharmaceuticals had its price target lowered by UBS Group AG from $37.00 to $33.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Syndax Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $44.00 to $40.00. They now have an “overweight” rating on the stock.
• 8/5/2026 – Syndax Pharmaceuticals had its “buy” rating reaffirmed by Bank of America Corporation.
• 8/5/2026 – Syndax Pharmaceuticals had its price target lowered by HC Wainwright from $40.00 to $38.00. They now have a “buy” rating on the stock.

Insider Transactions at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, CEO Michael Metzger sold 32,375 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $24.24, for a total value of $784,770.00. Following the transaction, the chief executive officer directly owned 484,843 shares of the company’s stock, valued at $11,752,594.32. The trade was a 6.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.80% of the stock is currently owned by insiders.

Syndax Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research programs target biological pathways involved in malignancy and immune-related conditions, with an emphasis on medicines that may address significant unmet medical needs.

Syndax’s lead product, Revuforj (revumenib), is an oral menin inhibitor approved by the U.S. Food and Drug Administration for treating relapsed or refractory acute leukemia with a KMT2A translocation in adults and pediatric patients aged one year and older.